Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara M Tolaney

Showing results (21-30 of 371) with videos related to

Pageof 38
Sort By:
Breast Cancer Research and Treatment|November 6, 2017
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a reviewRachel A Freedman, Sara M Tolaney
JAMA Oncology|August 29, 2024
Neoadjuvant Immunotherapy-From Trials to PracticeElizabeth A Mittendorf, Sara M Tolaney
Future Oncology (London, England)|December 5, 2015
The evolving understanding of small HER2-positive breast cancers: matching management to outcomesAdrienne G Waks, Sara M Tolaney
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Role of Immunotherapy in Triple-Negative Breast CancerTanya E Keenan, Sara M Tolaney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Reply to A.K. Goel et alSara M Tolaney, Eric P Winer
Oncotarget|March 22, 2021
Tumor mutational burden as a predictor of immunotherapy response in breast cancerTess A O'Meara, Sara M Tolaney
Current Treatment Options in Oncology|June 20, 2020
Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to GoRomualdo Barroso-Sousa, Sara M Tolaney
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 5, 2021
Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and BeyondRomualdo Barroso-Sousa, Sara M Tolaney
Anti-Cancer Agents in Medicinal Chemistry|March 12, 2009
Mechanisms of trastuzumab resistance in breast cancerSara M Tolaney, Ian E Krop
Expert Review of Anticancer Therapy|September 15, 2020
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacyRomualdo Barroso-Sousa, Sara M Tolaney
Pageof 38

Showing results (21-30 of 371) with videos related to

Sort By:
Pageof 38
Breast Cancer Research and Treatment|November 6, 2017
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a reviewRachel A Freedman, Sara M Tolaney
JAMA Oncology|August 29, 2024
Neoadjuvant Immunotherapy-From Trials to PracticeElizabeth A Mittendorf, Sara M Tolaney
Future Oncology (London, England)|December 5, 2015
The evolving understanding of small HER2-positive breast cancers: matching management to outcomesAdrienne G Waks, Sara M Tolaney
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Role of Immunotherapy in Triple-Negative Breast CancerTanya E Keenan, Sara M Tolaney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Reply to A.K. Goel et alSara M Tolaney, Eric P Winer
Oncotarget|March 22, 2021
Tumor mutational burden as a predictor of immunotherapy response in breast cancerTess A O'Meara, Sara M Tolaney
Current Treatment Options in Oncology|June 20, 2020
Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to GoRomualdo Barroso-Sousa, Sara M Tolaney
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 5, 2021
Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and BeyondRomualdo Barroso-Sousa, Sara M Tolaney
Anti-Cancer Agents in Medicinal Chemistry|March 12, 2009
Mechanisms of trastuzumab resistance in breast cancerSara M Tolaney, Ian E Krop
Expert Review of Anticancer Therapy|September 15, 2020
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacyRomualdo Barroso-Sousa, Sara M Tolaney
Pageof 38